Three generations of cyclosporine a formulations: an in vitro comparison.
When the microemulsion formulation of the critical dose drug cyclosporine A (CsA) (Sandimmun Optoral) was introduced in the mid-1990s, it became clear that this new formulation improves the oral bioavailability of CsA and has a positive influence on its pharmacokinetic variability. Previous studies with the original CsA formulation (Sandimmun) showed that the size of the emulsion droplets and concomitant food intake has an effect on the absorption of CsA from the small intestine when orally administered. It was suggested that these effects might have an influence on the drugs' pharmacokinetic parameters. In this study, we focused on the two above-mentioned aspects and compared the first and second generations of CsA products (Sandimmun, Sandimmun Optoral) to generic CsA formulations by analyzing the contents of cyclosporine A gel capsules with respect to their emulsion droplet and micelle sizes using photon correlation spectroscopy (PCS). We tried to discern any differences in droplet size between different generations of CsA formulations, primarily the second and third generation, through simple physical tests. Because a high fat content food may influence the absorption of CsA, we also determined the distribution of CsA between hydrophilic and lipophilic phases using high-performance liquid chromatography analysis. It became clear that when compared under simple physical conditions, established cyclosporine formulations and new generic products show significant differences in droplet size and distribution between an aqueous phase and a high fat content food. Whether these differences are of clinical relevance remains to be investigated.
Thomas
Katrin
K
Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany.
Koelwel
Christoph
C
Machei
Uwe
U
Färber
Lothar
L
Göpferich
Achim
A
D002214:Capsules; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D016572:Cyclosporine / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016568:Drugs, Generic / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D004655:Emulsions; D005750:Gastric Juice / Q000737:chemistry; D005782:Gels; D007166:Immunosuppressive Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D008823:Micelles; D010316:Particle Size; D013810:Therapeutic Equivalency
D002214:Capsules; D016568:Drugs, Generic; D004655:Emulsions; D005782:Gels; D007166:Immunosuppressive Agents; D008823:Micelles; D016572:Cyclosporine